Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis Collection

Not Applicable

Recruiting

• Conditions: Paraneoplastic Neurological Syndromes or Autoimmune Encephalitis
• Interventions: Biological: Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.

• Registration Number: NCT05198661
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Numerous neurological disorders affecting the central and peripheral nervous system can be attributed to the immune system through multiple effector mechanisms. However, current treatments could be drastically improved by faster and more accurate diagnosis. The sample collection will benefit to patients with rare neuroimmune syndromes such as Autoimmune Encephalitis (AE) and Paraneoplastic Neurological Syndromes (PNS) leading to a better and early diagnosis, as well as treatment improvement.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2021-12-20
• Study First Submitted QC: 2022-01-06
• Study First Posted: 2022-01-20
• Study Start: 2022-08-02
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-27
• Last Update Posted: 2024-02-29
• Primary Completion: 2032-08-02
• Study Completion: 2032-08-02

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 3500

Inclusion Criteria

• Patient with consent
• Patient with well-characterized antibodies in serum or cerebrospinal fluid or not
• Patient with neurological disorder compatible with PNS or auto-immune encephalitis

Read More

Exclusion Criteria

• Refusal of consent
• Patient under guardianship

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Paraneoplastic neurological syndrome patients and autoimmune encephalitis patient	Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.	patients with diagnosis of paraneoplastic neurological syndrome or autoimmune encephalitis

Primary Outcome Measures

Name	Time	Method
Blood Samples	10 years	Assessment of biocollection of blood samples
Cerebrospinal fluid biocollection	10 years	Assessment of biocollection of Cerebrospinal fluid

Secondary Outcome Measures

Name	Time	Method
Scientific collaboration	10 years	Number of project issued from the biocollection
Scientific	10 years	Number of scientific papers issued from the biocollection

Trial Locations

Locations (16)

Intensive Care Medicine; 🇫🇷 Paris, France

General neurology; 🇫🇷 Annecy, France

Adult Neurology and Neuropsychology; 🇫🇷 Marseille, France

Vascular and general neurology; 🇫🇷 Rouen, France

Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes; 🇫🇷 Lyon, France

Neuropediatrics; 🇫🇷 Paris, France

Onco-neurology; 🇫🇷 Paris, France

Neurologie; 🇫🇷 Tours, France

Intensive care medicine; 🇫🇷 Cannes, France

General, Vascular and Degenerative Neurology; 🇫🇷 Dijon, France

Internal and general practitioner; 🇫🇷 Gap, France

Neurology adult; 🇫🇷 Paris, France

Neurology; 🇫🇷 Épinal, France

General Neurology; 🇫🇷 Montpellier, France

General medicine; 🇫🇷 Mulhouse, France

Neurology, neuropsychology and language rehabilitation; 🇫🇷 Poitiers, France